No April Fool’s Joke: MannKind’s Afrezza Flies Through FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Inhaled insulin gains advisory committee endorsement in both type 1 and 2 populations. Given efficacy questions and potential safety concerns, panelists suggest patients who would most benefit include those with limited ability to self-inject and who need additional glycemic control in between meals.
You may also be interested in...
FDA Sets Up Afrezza Panel To Split Between Type 1 And 2 Diabetes
Agency briefing documents for April 1 meeting suggest greater efficacy concerns in type 1 diabetics, although review of most recent trial in type 2 patients cites “surprisingly modest” treatment effects compared to other drugs. Safety issues for panel consideration include pulmonary function effects and lung cancer.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.